Screener
Protagonist Therapeutics PTGX Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Protagonist Therapeutics’s reported figures.
Based on the most recent quarter.
The source filing: Protagonist Therapeutics’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091123
FAQ
- What is Protagonist Therapeutics's debt-to-equity?
- Protagonist Therapeutics (PTGX) reported debt-to-equity of 0× in Q2 2026.
- How has Protagonist Therapeutics's debt-to-equity changed year-over-year?
- Protagonist Therapeutics's debt-to-equity decreased by 34.9% year-over-year, from 0× to 0×.
- What is the long-term trend for Protagonist Therapeutics's debt-to-equity?
- Over 5 years (2020 to 2025), Protagonist Therapeutics's debt-to-equity has grown at a -4.6% compound annual growth rate (CAGR), from 0× to 0×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Protagonist Therapeutics's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude